Evidence map›Paper›PMID 35122898›Full record

ArticleBrain research bulletin2022

The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting.

Gabriele Floris, Simona Scheggi, Romina Pes, Marco Bortolato

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain research bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Neurosteroid influence on affective tone.Neuroscience and biobehavioral reviews · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Gabriele FlorisDept. of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
Simona ScheggiDept. of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT, USA; Dept. of Molecular and Developmental Medicine, School of Medicine, University of Siena, Italy.
Romina PesDept. of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS, USA.
Marco BortolatoDept. of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT, USA; Dept. of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS, USA. Electronic address: marco.bortolato@utah.edu.
University of Kansas · USUniversity of Utah · US

Funding

Exploring steroid-based therapies to reduce opioid abuseR21DA049530 · NIDA · UNIVERSITY OF UTAH · PI BORTOLATO, MARCO, PETERSON, RANDALL T · 2020 to 2021
$419k
NIDA NIH HHS R21 DA049530
6 · The paper itself

Abstract

Pramipexole is a potent agonist of D

Indexed as

Probability Learning5-alpha Reductase InhibitorsAnimalsBehavior, AnimalChoice BehaviorDisease Models, AnimalDopamine AgonistsFinasterideImpulsive BehaviorNucleus AccumbensPramipexoleRatsReceptors, Dopamine D35-alpha Reductase InhibitorsDopamine AgonistsDrd3 protein, ratFinasteridePramipexoleReceptors, Dopamine D3D(3) dopamine receptorsFinasterideNucleus accumbensPramipexoleProbability discounting

Identifiers

PMID35122898
PMCPMC9012661
OpenAlexW4210633587

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.